Allowing Greater Access to Safe and Effective Contraception Act
Summary
HR8083 is an early-stage bill (referred to four committees) that would incentivize OTC switches for routine oral contraceptives via priority review and fee waivers for drugmakers. No explicit funding is authorized — only a GAO study on federal contraceptive funding is directed. At this procedural stage, the bill has zero binding market impact. Pfizer ($PFE at $26.69, down -4.95% over 30 days) and Bristol-Myers Squibb ($BMY at $59.64, down -1.67% over 30 days) have no current revenue exposure to this pathway.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8083 is early-stage with zero binding market impact — referred to four committees with no hearings scheduled.
- 2.No federal funding is authorized or appropriated; the bill only waives FDA user fees for OTC switch applications.
- 3.Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) have minimal contraceptive revenue exposure; the bill does not affect their primary businesses.
- 4.Pure-play contraceptive manufacturers (Teva, AbbVie) could see optionality benefits IF the bill passes AND they choose to file an OTC switch — both are uncertain.
- 5.No signal in price action: $PFE (-4.95% 30d) and $BMY (-1.67% 30d) show no correlation with this legislative action.
Market Implications
No immediate market implications. HR8083 is a procedural early-stage bill that creates no funding, no procurement, no tax changes, and no binding regulatory requirement. The OTC switch pathway is optional for manufacturers, and the bill's passage probability is low given its divided referral and lack of Senate companion. Retail investors should ignore this bill until (and unless) it advances to a committee markup, which would indicate real legislative momentum. Current price trends for ($26.69, trending down) and ($59.64, bouncing but trending down over 30 days) are driven by fundamentals (patent cliffs, pipeline sentiment, interest rates), not this bill.
Full Analysis
-
What happened: On March 25, 2026, Rep. Hinson (R-IA) introduced HR8083, the "Allowing Greater Access to Safe and Effective Contraception Act." The bill was referred to four committees — Energy and Commerce, Ways and Means, Natural Resources, and Armed Services — indicating a broad jurisdictional scope. This is the only action; the bill is in early-stage committee review with no markups or hearings scheduled. The bill's core mechanism is simple: it directs the FDA to grant priority review and waive application fees for any manufacturer filing a supplemental new drug application (sNDA) to switch an existing prescription oral contraceptive (for routine use, not emergency or abortifacient) to OTC status for adults age 18+. Individuals under 18 would remain prescription-only.
-
The money trail: There is NO direct federal spending or tax expenditure created by this bill. Section 2(c) waives the fee for the OTC switch application — that fee is typically ~$2M for a standard application requiring clinical data. The waiver reduces a private cost to drugmakers, not a federal outlay. Section 3 directs the GAO to conduct a study on federal funding of contraceptive methods — this is a study, not an appropriation. No funding is authorized or appropriated. The fiscal impact is limited to administrative costs for FDA review, which are already covered by user fees. This is an authorization bill with no appropriation rider.
-
Structural winners and losers: The primary beneficiaries would be drugmakers with existing oral contraceptive franchises who could afford the clinical trials required for an OTC switch. Teva ($TEVA, generic contraceptive leader), AbbVie ($ABBV through its legacy Allergan portfolio — Lo Loestrin FE, etc.), and Bayer (privately held, not tradeable on US exchanges) are the largest players in oral contraceptives. Among US-listed pure-plays, has legacy oral contraceptive products via its established products division (Nordette, Lo/Ovral generics) but this is a minimal revenue line. has no significant contraceptive portfolio post-Celgene integration. Neither company is structurally positioned to benefit significantly. The bill provides no direct procurement, no tax credits, and no guaranteed revenue. The impact is purely optional: it lowers the regulatory cost for manufacturers who choose to pursue OTC status. Given the early legislative stage (referred to four committees, no Senate companion), passage probability is low.
-
Market data context: As of April 30, 2026, trades at $26.69, near the bottom of its 52-week range ($21.97-$28.75), with a 30-day decline of -4.95% and a 7-day decline of -1.15%. trades at $59.64, near its 52-week high ($42.52-$62.89), showing a 7-day bounce of +1.58% but a 30-day decline of -1.67%. Neither stock shows any price action correlation to HR8083 — the bill's introduction date (March 25) shows no anomalous volume or price movement in either name. The current price trends reflect broader sector dynamics (sector rotation out of pharma, patent cliffs) rather than legislative catalysts.
-
Timeline: HR8083 has passed its only procedural hurdle — introduction and committee referral. It must now be considered by all four referred committees. Given the divided referral to Armed Services and Natural Resources (unusual for a contraceptive bill), jurisdictional disputes may slow progress. No companion bill exists in the Senate. For the bill to become law, it must pass both chambers in identical form and be signed by the President. No hearings have been scheduled. This is a low-velocity, early-stage procedural action with no market-moving potential in the near term.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Limited confirming evidence — causal thesis exists but few external signals
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.
Protect Infant Formula from Contamination Act
Skinny Labels, Big Savings Act
Most Favored Patient Act of 2026
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
Skinny Labels, Big Savings Act
Protecting Americans from Unsafe Drugs Act of 2026
Elijah E. Cummings Family Asthma Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
National Homeownership Month, 2026
This proclamation formalizes National Homeownership Month and details several ongoing or proposed policy actions: Fannie Mae and Freddie Mac are directed to purchase $200 billion in mortgage-backed securities to lower borrowing costs; an executive order bans large institutional investors from buying single-family homes; and the Administration calls on Congress to pass the 21st Century ROAD to Housing Act to make these reforms permanent. The action also reaffirms efforts to restrict taxpayer-backed loans to only law-abiding citizens, targeting fraud and illegal immigration as a means to improve housing affordability.
Restoring American Commercial Fishing in the Pacific
This proclamation reverses prior national monument fishing bans in the Pacific by reopening hundreds of thousands of square miles of waters in Papahānaumokuākea Marine National Monument, Mariana Trench Marine National Monument, and Rose Atoll Marine National Monument to commercial fishing. It directs the Secretary of Commerce to amend or repeal inconsistent regulations, allows only US-flagged vessels to fish commercially (with limited permits for foreign transport vessels), and reaffirms that all fishing remains subject to existing federal conservation laws such as the Magnuson-Stevens Act, Endangered Species Act, and Marine Mammal Protection Act.
Strengthening Customs Enforcement
This executive order directs the Secretary of Homeland Security to revise customs enforcement regulations within 180 days, requiring importers of record (IORs) to maintain minimum tangible domestic assets or bonding, disclose ownership and business affiliations, and maintain good standing with CBP. It prohibits foreign IORs from filing informal entries for low-value articles and imposes additional bonding and CTPAT validation requirements for foreign IORs on formal entries, aiming to enhance compliance and revenue collection.